EPISODE · Oct 27, 2023 · 29 MIN
Virginia Focus - Medicare & Alzheimers Meds
from Virginia Focus
More than six million Americans are currently living with Alzheimer's disease and by 2050, that number is expected to skyrocket to 13 million. The FDA approved two new treatments that slow the progression of the disease, but the Centers for Medicare and Medicaid Services, also known as CMS, is setting a dangerous precedent by requiring consent from patients in a way that's never been demanded before. Now many doctors, elected leaders, and families are afraid patients will face health disparities and that the move could be expanded to limit access to other medications. Let's hear more from the Chairman of the Partnership to Fight Chronic Disease and Chairman of Health Policy and Management at Emory University, Dr. Kenneth Thorpe.
What this episode covers
More than six million Americans are currently living with Alzheimer's disease and by 2050, that number is expected to skyrocket to 13 million. The FDA approved two new treatments that slow the progression of the disease, but the Centers for Medicare and Medicaid Services, also known as CMS, is setting a dangerous precedent by requiring consent from patients in a way that's never been demanded before. Now many doctors, elected leaders, and families are afraid patients will face health disparities and that the move could be expanded to limit access to other medications. Let's hear more from the Chairman of the Partnership to Fight Chronic Disease and Chairman of Health Policy and Management at Emory University, Dr. Kenneth Thorpe.
NOW PLAYING
Virginia Focus - Medicare & Alzheimers Meds
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.